Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy
Eugene J. Pietzak(Memorial Sloan Kettering Cancer Center), Emily C. Zabor(Memorial Sloan Kettering Cancer Center), Aditya Bagrodia(Memorial Sloan Kettering Cancer Center), Joshua Armenia(Memorial Sloan Kettering Cancer Center), Wenhuo Hu(Memorial Sloan Kettering Cancer Center), Ahmet Zehir(Memorial Sloan Kettering Cancer Center), Samuel A. Funt(Memorial Sloan Kettering Cancer Center), François Audenet(Memorial Sloan Kettering Cancer Center), David Barron(Memorial Sloan Kettering Cancer Center), Noelia Maamouri(Memorial Sloan Kettering Cancer Center), Qiang Li(Memorial Sloan Kettering Cancer Center), Min Yuen Teo(Memorial Sloan Kettering Cancer Center), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Michael F. Berger(Memorial Sloan Kettering Cancer Center), Nikolaus Schultz(Memorial Sloan Kettering Cancer Center), Guido Dalbagni(Memorial Sloan Kettering Cancer Center), Harry W. Herr(Memorial Sloan Kettering Cancer Center), Dean F. Bajorin(Memorial Sloan Kettering Cancer Center), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Hikmat Al‐Ahmadie(Memorial Sloan Kettering Cancer Center), Bernard H. Bochner(Memorial Sloan Kettering Cancer Center), David B. Solit(Memorial Sloan Kettering Cancer Center), Gopa Iyer(Memorial Sloan Kettering Cancer Center)
Cited by 152Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis